BIOSENIC SA (BIOS.BR) Stock Price, Forecast & Analysis
Europe - Euronext Brussels - EBR:BIOS - BE0974280126 - Common Stock
BIOS.BR Key Statistics, Chart & Performance
The current stock price of BIOS.BR is 0.0024 EUR. In the past year, price decreased by -61.9%.
BIOS.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 71.25 | 46.32B | ||
| ARGX.BR | ARGENX SE | 70.53 | 45.86B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.00B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.34B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.40B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.73B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 1CVAC.MI | CUREVAC NV | 5.04 | 987.60M | ||
| NANO.PA | NANOBIOTIX | N/A | 911.27M | ||
| 5CV.DE | CUREVAC NV | 6.93 | 905.18M | ||
| IVA.PA | INVENTIVA SA | N/A | 726.82M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M |
Related stock screener links
About BIOS.BR
Company Profile
BioSenic SA is a biotech company engaged in the development of clinical assets . The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 3 full-time employees. The company went IPO on 2015-02-06. The firm develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. The company is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation. The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration. The company also provides cell therapy platform for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO (Arsenic trioxide/ Oral arsenic trioxide).
Company Info
BIOSENIC SA
Rue Granbonpre 11, Batiment H (bte 24)
Mont-Saint-Guibert BRABANT-WALLON BE
Employees: 3
Phone: 32493097366
BIOSENIC SA / BIOS.BR FAQ
What does BIOSENIC SA do?
BioSenic SA is a biotech company engaged in the development of clinical assets . The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 3 full-time employees. The company went IPO on 2015-02-06. The firm develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. The company is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation. The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration. The company also provides cell therapy platform for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO (Arsenic trioxide/ Oral arsenic trioxide).
Can you provide the latest stock price for BIOSENIC SA?
The current stock price of BIOS.BR is 0.0024 EUR. The price increased by 9.09% in the last trading session.
What is the dividend status of BIOSENIC SA?
BIOS.BR does not pay a dividend.
What is the ChartMill rating of BIOSENIC SA stock?
BIOS.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is BIOS.BR stock listed?
BIOS.BR stock is listed on the Euronext Brussels exchange.
What is the GICS sector and industry of BIOS stock?
BIOSENIC SA (BIOS.BR) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for BIOS stock?
BIOSENIC SA (BIOS.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).
BIOS.BR Technical Analysis
BIOS.BR Financial Highlights
Over the last trailing twelve months BIOS.BR reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 90.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |